Actos Bladder Cancer Lawsuit
Actos link to bladder cancer causes sales to drop

The link between Actos medication and bladder cancer has caused sales for Takeda Pharmaceuticals to drop in recent months. New FDA warnings and growing concerns with Actos link to bladder cancer is believed to be the reason behind these losses.

Takeda Pharmaceuticals, Japan’s largest drug maker, reports that sales from Actos were only $1.74 billion prior to September of 2011. The drug company also estimates that 31% of its profits will drop by March of 2012.

Actos (pioglitazone) was first introduced in July of 1999 and was designed to aid the body’s sensitivity to insulin in patients that have been diagnosed with type II diabetes. Since its release, Actos became Takeda Pharmaceuticals best selling drug with record sales of $4.3 billion in 2010.

Though Actos performed well for the company’s profits in 2010, a number of reported bladder cancer cases began to surface, causing the Food and Drug Administration to intervene in that same year.  In September of 2010, FDA officials released information regarding an on-going ten year study of Actos linking the drug to bladder cancer when taken over a period of 12 months or more.

Health regulators in France ordered an Actos recall in June 2011 after a report indicated an increased risk for bladder cancer with use of Actos.

In August of 2011, the FDA approved new warning labels for Actos. These new warning labels informed patients of the dangers of Actos if taken for 12 months or more.

Sales for Takeda Pharmaceuticals may continue to fall as more victims pursue lawsuits against the company. Currently, Takeda is aware of 54 cases in the United States, however, that number is expected to grow. Meanwhile, the U.S. District Panel on Multidistrict Litigation is scheduled for an oral hearing on December 1, 2011 to discuss whether Actos lawsuits should be centralized before one judge for pretrial proceedings.


About the Contributor

Related Posts